|Bid||189.26 x 50000|
|Ask||190.52 x 50000|
|Day's Range||188.96 - 192.32|
|52 Week Range||155.54 - 250.00|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||5.36|
|Forward Dividend & Yield||4.86 (2.56%)|
|Ex-Dividend Date||Jul 23, 2021|
|1y Target Est||194.41|
Subscribe to Yahoo Finance Plus to view Fair Value for VOW3.FLearn more
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collaboration to study biomarker data from Alligator's OPTIMIZE-1 study with the University of Pennsylvania's (UPENN) Pancreatic Cancer Research Center.
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company's lead asset, mitazalimab. All patients in the 450 µg/kg cohort have been dosed and there have been no adverse effects related to study medication has been reported. Dosing of the 900 µg/kg cohort has been initiated. The Phase 1b part of the study is expected to be completed during Q1 2022.
Tianjin, a key port in northern China, reported 18 domestically transmitted cases with confirmed symptoms for Monday, National Health Commission (NHC) data showed on Tuesday. NHC official He Qinghua said on Saturday the risk of the Tianjin outbreak spreading to other areas was gradually declining, as new cases in the past three days were mainly in people who had been quarantined. The China unit of U.S. planemaker Boeing said on Tuesday that a small number of employees has been impacted by various "community-level lockdowns" during the Tianjin outbreak.